Nordea: Analysts overlook daratumumab’s potential
Johnson & Johnson said last week that it has 10 potential blockbusters in its pipeline, including Genmab’s daratumumab. But most analysts have yet to discover the true potential of the cancer contender, says Nordea.
BY LONNI LYNGE
Johnson & Johnson’s confident and optimistic management team announced last week that it expects to submit applications for 10 new pharmaceutical products, each with the potential to generate revenue of more than USD 1 billion at its peak.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danske: Genmab partner might accelerate launch
For abonnenter
Increased belief in Genmab’s potential blockbuster
For abonnenter
Genmab CEO sees bright future
For abonnenter
